Stål O, Carstensen J, Hatschek T, Nordenskjöld B
Department of Oncology, University Hospital, Linköping, Sweden.
Br J Cancer. 1992 Oct;66(4):706-11. doi: 10.1038/bjc.1992.342.
Tumours from 336 breast cancer patients under the age of 50 were analysed for hormone receptor content and by DNA flow cytometry. Sixty-six percent of the tumours were positive for estrogen receptors (ER), 60% were progesterone receptor (PR) positive and 42% showed DNA diploid profiles. DNA hypodiploid tumours were relatively frequent (7%), especially in patients aged 40 years or less (11%). S-phase fraction (SPF), with a mean of 10%, correlated significantly with receptor status, DNA ploidy, lymph node status, tumour size and age. With a median follow-up period of 34 months, the distant recurrence-free interval was independently predicted by lymph node status, tumour size, SPF and PR content. Amongst the 212 patients who had not received adjuvant systemic treatment, receptor status was, in addition to lymph node status and SPF, independently related to distant recurrence rate. A high SPF identified a subgroup with high recurrence rate, comprising approximately one third of the node-negative patients. Similarly, the one third of node-positive patients who had PR-positive tumours with a low S-phase fraction formed a subgroup with low recurrence rate. We conclude that hormone receptor assays and DNA flow cytometry should be useful tools in the management of breast cancer patients less than 50 years of age.
对336例年龄在50岁以下的乳腺癌患者的肿瘤进行了激素受体含量分析和DNA流式细胞术检测。66%的肿瘤雌激素受体(ER)呈阳性,60%孕激素受体(PR)呈阳性,42%显示DNA二倍体图谱。DNA亚二倍体肿瘤相对常见(7%),尤其是在40岁及以下的患者中(11%)。S期分数(SPF)平均为10%,与受体状态、DNA倍性、淋巴结状态、肿瘤大小和年龄显著相关。中位随访期为34个月,远处无复发生存期由淋巴结状态、肿瘤大小、SPF和PR含量独立预测。在212例未接受辅助全身治疗的患者中,除淋巴结状态和SPF外,受体状态还与远处复发率独立相关。高SPF确定了一个高复发率亚组,约占淋巴结阴性患者的三分之一。同样,三分之一的淋巴结阳性患者,其PR阳性肿瘤且S期分数低,形成了一个低复发率亚组。我们得出结论,激素受体检测和DNA流式细胞术应是50岁以下乳腺癌患者管理中的有用工具。